Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sanofi, Novo Nordisk...

    Sanofi, Novo Nordisk Eli Lilly accused of deceptive drug pricing of Insulin

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-10-17T15:16:45+05:30  |  Updated On 13 Aug 2021 5:16 PM IST

    US : Minnesota's attorney general on Tuesday filed a lawsuit accusing drug manufacturers Sanofi SA, Novo Nordisk and Eli Lilly and Co of deceptively raising prices for insulin.


    In a lawsuit filed in federal court in Trenton, New Jersey, Minnesota Attorney General Lori Swanson took aim at the companies after the list price for some insulin products more than tripled since 2002.


    The lawsuit alleged that companies fraudulently set artificially high list price for their products while offering rebates to pharmacy benefit managers (PBMs) in exchange for them covering the drug on behalf of health plans.


    PBMs negotiate drug prices for employers and health plans and typically demand hefty discounts off list price from drugmakers in exchange including the medicines on their preferred formularies.


    The lawsuit contended that the list prices the drug companies set were so far from those net prices that they did not accurately approximate the true cost of insulin and were deceptive and misleading.


    The practice made insulin less affordable for diabetes patients in high deductible health plans, the uninsured and senior citizens covered by the government Medicare healthcare program, the suit contended.


    "Many people can't afford the price hikes but can't afford to stop taking the medication either," Swanson said in a statement.


    Danish drugmaker Novo Nordisk in a statement said it was "committed to ethics and compliance in how we support patients." French drugmaker Sanofi and Indianapolis-based Lilly in separate statements said they believed the case was without merit.


    The lawsuit comes amid continued concerns about rising U.S. drug costs, particularly for insulin, a hormone needed by many people with diabetes to control blood sugar levels.


    Swanson's lawsuit marked the first by a state to target pricing practices of insulin manufacturers. The case was filed in New Jersey, where a similar proposed class action lawsuit is pending.


    Two other states, Washington and New Mexico, have been conducting similar investigations, according to Novo Nordisk.


    Novo's insulin products include Levemir, whose cost according to Swanson has risen from $120.64 per vial in 2012 to $293.75 in 2018. There have been similar price hikes for Lilly's HumaLog and Sanofi's Lantus, the lawsuit said.


    The lawsuit seeks an injunction preventing the companies from disseminating misleading list prices for insulin products. It also seeks damages for Minnesota residents who paid out-of-pocket for their insulin.


    But it comes a day after the U.S. government said it would propose requiring drugmakers to include the list price of prescription medicines in television commercials.

    DrugmakersEli LillyFrench drugmaker Sanofigovernment Medicare healthcare programhealth planshormoneinsulininsulin makersMinnesotaNovo Nordiskpharmacy benefit managersSanofi’s LantusSwanson

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok